10-Q: Ispire Tech Revenue Plummets 51.5%, Equity Turns Negative

Ispire Technology Inc. reported a sharp decline in revenue and a shift to negative stockholders' equity for the quarter ended December 31, 2025, despite reducing its net loss.

Summary

• Revenue for the three months ended December 31, 2025, decreased by 51.5% to $20.3 million from $41.8 million in the prior year period.
• Revenue for the six months ended December 31, 2025, decreased by 37.6% to $50.6 million from $81.2 million in the prior year period.
• Net loss for the three months ended December 31, 2025, improved to $(6.6) million, or $(0.12) per share, from $(8.0) million, or $(0.14) per share, in the prior year.
• Net loss for the six months ended December 31, 2025, improved to $(9.9) million, or $(0.17) per share, from $(13.6) million, or $(0.24) per share, in the prior year.
• Gross profit decreased by 55.0% for the three months and 44.0% for the six months ended December 31, 2025, with gross margin declining to 17.1% and 17.0% respectively.
• Operating expenses decreased significantly by 31.4% for the three months and 35.1% for the six months, primarily due to reductions in sales and marketing, payroll, and legal/professional fees.
• Total stockholders' equity shifted to a deficit of $(7.7) million as of December 31, 2025, from a positive equity of $0.6 million as of June 30, 2025.
• Working capital increased substantially to $3.5 million as of December 31, 2025, from $0.4 million as of June 30, 2025.
• Net cash used in operating activities was $(5.2) million for the six months ended December 31, 2025, a significant shift from $0.4 million provided in the prior year period.
• Material weaknesses in internal controls over financial reporting were identified, including lack of controls for significant estimates, insufficient accounting personnel, and inadequate IT general controls.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging quarter with substantial revenue contraction and a shift to negative equity, despite effective cost management leading to a reduced net loss. The identified material weaknesses in internal controls and ongoing regulatory pressures are significant concerns.

Positives

• Net loss decreased by $1.4 million for the three months and $3.7 million for the six months ended December 31, 2025, compared to the prior year periods.
• Operating expenses were significantly reduced by $4.7 million (31.4%) for the three months and $9.8 million (35.1%) for the six months, demonstrating effective cost control.
• Working capital increased substantially by 840.8% to $3.46 million as of December 31, 2025, from $0.37 million as of June 30, 2025.
• Net cash used in investing activities decreased to $(0.9) million for the six months ended December 31, 2025, from $(1.1) million in the prior year period.
• Management believes current cash and cash flows from operations, equity offerings, and borrowing will be sufficient to meet working capital needs for the next 12 months.

Negatives

• Revenue decreased significantly by 51.5% for the three months and 37.6% for the six months ended December 31, 2025, indicating substantial market contraction or loss of sales.
• Gross profit decreased by 55.0% for the three months and 44.0% for the six months, with gross margins declining from 18.5% to 17.1% and 19.0% to 17.0% respectively.
• Total stockholders' equity shifted from a positive $604,694 to a deficit of $(7,663,417) as of December 31, 2025.
• Net cash flow from operating activities shifted from a positive $428,110 to a negative $(5,150,391) for the six months ended December 31, 2025.
• Cash balance decreased to $17.6 million as of December 31, 2025, from $24.4 million as of June 30, 2025.
• High customer concentration with Customer A accounting for 38% of revenue for the three months and 31% for the six months ended December 31, 2025.
• Significant supplier concentration with Shenzhen Yi Jia (a related party) accounting for 97% of purchases for the three months and 94% for the six months ended December 31, 2025.
• Credit loss expenses remained high at $4.2 million for the three months and $6.0 million for the six months ended December 31, 2025.

Risks

• Government regulations on e-cigarettes and cannabis vaping products vary globally and can change swiftly, potentially making products non-compliant and disrupting business.
• The Federal Food, Drug, and Cosmetic Act requires Premarket Tobacco Product Applications (PMTAs) for ENDS products in the U.S., and FDA may reject applications, preventing sales.
• Amendments to the PACT Act place significant burdens on sellers of vaping products in the U.S., potentially making profitable operation difficult.
• Cannabis and its derivatives with over 0.3% delta-9 THC remain Schedule I controlled substances under U.S. federal law, prohibiting manufacture and distribution.
• The European Commission's Tobacco Products Directive (TPD) regulates e-cigarettes in the EU, requiring product sales applications and compliance with packaging, labeling, and ingredient rules.
• The sale of cannabis vaping products is illegal in the European Union and the United Kingdom.
• The business relies on timely collection of accounts receivable, and failure to collect due to adverse economic conditions, ineffective collection efforts, or disputes could impair profitability.
• High dependence on a single major supplier, Shenzhen Yi Jia (a related party), for the majority of vaping product purchases creates supply chain risk.
• Concentration of credit risk exists with cash balances exceeding FDIC/PIDM/HKD insured limits, totaling $17.2 million in excess as of December 31, 2025.
• Concentration of accounts receivable with a few major customers (Customers D and E each accounted for 16% of total accounts receivable as of December 31, 2025).
• Material weaknesses in internal controls over financial reporting, including lack of controls for significant estimates (inventory and credit loss reserves), insufficient accounting personnel, and inadequate IT general controls.
• Potential future financing, if required, may involve additional debt or the sale of additional equity securities, which could result in substantial dilution to stockholders.
• Restrictions on cash transfer from the Hong Kong operating subsidiary to U.S. investors could arise if the subsidiary incurs additional debt.

Future Outlook

The company plans to continue developing its sales network for cannabis vaping products across Europe, South America, and other regions in preparation for future legalization. Management anticipates that current cash and cash flows from operations, along with proceeds from equity offerings and borrowing, will be sufficient to cover working capital needs for the next 12 months. The office and production plant under construction in Malaysia are expected to be operational during fiscal year 2026.

Management Comments

• "We are committed to delivering superior products that challenge industry norms, with the goal of delivering an unmatched customer and adult consumer experience."
• "Risk reduction is central to our mission, and we aim to improve the lives of our consumers through cutting-edge research and development."
• "Our technology platforms look to reduce youth access to vaping products, which in turn we believe will facilitate our ability to provide adult consumers with the products they desire."
• "Due to federal status of cannabis and the uncertainty of adverse economic conditions in cannabis industry, the Company has focused more on nicotine business in the past year."
• "As of the date of this Quarterly Report, we believe that our current cash and cash flows provided by operating activities, and the net proceeds from our equity offerings and borrowing will be sufficient to meet our working capital needs in the next 12 months."
• "Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud."

Industry Context

StockSavvy.ai notes that Ispire Technology Inc. operates within a highly regulated and evolving vaping industry, facing stringent government oversight for both nicotine and cannabis products globally. The company's strategic shift to focus more on the nicotine business, while expanding its cannabis sales network internationally in anticipation of legalization, reflects the complex regulatory landscape and market uncertainties, particularly regarding the federal status of cannabis in the U.S. The significant revenue decline suggests intense competition or adverse market conditions impacting its core product lines.

Corporate Governance

Legal Proceedings

• The company is not a party to, nor is it aware of, any legal or regulatory proceedings, investigations, or claims which are likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Tuanfang Liu (Co-CEO & Chairman) and Jiangyan Zhu (wife, director) beneficially own 58.0% and 4.4% of Ispire Technology Inc. respectively, and control Aspire Global (66.5% and 5.0% respectively).
• The majority of tobacco and cannabis vaping products were purchased from Shenzhen Yi Jia, a Chinese company 95% owned by the Co-CEO and 5% by his cousin.
• Purchases from Shenzhen Yi Jia amounted to $15,695,034 for the three months and $38,596,402 for the six months ended December 31, 2025.
• Accounts payable to Shenzhen Yi Jia totaled $42,444,624 as of December 31, 2025.
• A non-current amount due to Shenzhen Yi Jia of $29,000,000 as of December 31, 2025, was reclassified from accounts payable, with repayment deferred for 12 months starting February 6, 2026.
• The company has a 40% membership interest in IKE Tech LLC, a joint venture.
• Accounts receivable from IKE Tech LLC totaled $156,853 as of December 31, 2025.
• Other income from IKE Tech LLC (administrative fees) was $112,082 for the three months and $122,214 for the six months ended December 31, 2025.
• A joint venture investment payable to IKE Tech LLC of $5,307,863 was recorded as of December 31, 2025.
• Ispire entered into an exclusive supply agreement with Berify (a JV partner) to purchase all Bluetooth enabled integrated circuits for IKE at cost plus a 20% mark-up.
• IKE Tech LLC entered into an exclusive supply agreement with Ispire to purchase all nicotine products to be sold by IKE at cost plus a 5% mark-up.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity raises and negative impact on share price due to significant revenue decline, negative equity, and internal control weaknesses.
• **Employees**: Experienced a decrease in headcount in North America, leading to reduced payroll and stock-based compensation expenses.
• **Customers**: Shorter credit terms implemented in the United States, focusing on higher quality customers, which may affect customer relationships or sales volume.
• **Suppliers**: High reliance on Shenzhen Yi Jia, a related party, for the majority of product purchases, creating concentration risk.
• **Creditors**: Shenzhen Yi Jia, a significant related-party creditor, agreed to defer repayment of $29 million, indicating the company's reliance on related-party financing.

Next Steps

• Continue to develop and implement internal controls over financial reporting to address identified material weaknesses.
• Focus on improving controls related to evaluating significant estimates, particularly inventory and credit loss reserves.
• Recruit and retain sufficient personnel with appropriate accounting knowledge and experience to handle complex U.S. GAAP issues and financial statement preparation/review.
• Enhance IT general controls, including cyber security governance, logical access security, and service organization management.
• Bring the office and production plant under construction in Malaysia into use during fiscal year 2026.
• Continue developing the sales network for cannabis vaping products across Europe, South America, and other regions in anticipation of legalization.

Key Dates

Recommendation

Ispire Technology Inc. faces substantial headwinds, evidenced by a 51.5% revenue decline in the quarter and a 37.6% decline for the six months ended December 31, 2025. While net loss improved, this was primarily driven by significant cost reductions rather than revenue growth. The company's shift to a negative stockholders' equity position and material weaknesses in internal controls over financial reporting are critical concerns. High dependence on a related-party supplier and the volatile regulatory environment for vaping products further exacerbate risks. Given these factors, a "sell" recommendation is warranted for investors seeking to mitigate exposure to a company with significant operational and financial challenges.

Keywords

Vaping, E-cigarettes, Cannabis vaping, SEC 10-Q, Financial results, Revenue decline, Net loss, Operating expenses, Gross profit, Regulatory risk, PMTA, PACT Act, TPD, Internal controls, Related party transactions, Liquidity, Capital resources, Ispire Technology Inc., ISPR